• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Sophia Adamia, PhD


  • Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.Blood. 2014 May 1(18):2816-25.
  • Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD.A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Clin Cancer Res. 2014 Mar 1;20(5):1135-45.
  • Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD.Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?.Curr Cancer Drug Targets. 2013 Sep;13(7):735-48.
  • Adamia S, Pilarski PM, Belch AR, Pilarski LM.Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.Curr Cancer Drug Targets. 2013 May;13(4):347-61. Review.
  • Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD.Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells.PLoS ONE. 2011;6(9):e25351.
  • Amin SB, Shah PK, Yan A, Adamia S, Minvielle S, Avet-Loiseau H, Munshi NC, Li C.The dChip survival analysis module for microarray data.BMC Bioinformatics. 2011;12:72.
  • Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Blood. 2011 Feb 14.
  • Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD.Discovery and characterization of novel mutant FLT3 kinase inhibitors.Mol Cancer Ther. 2010 Sep;9(9):2468-77.
  • Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray N, Griffin JD.Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.Blood. 2010 May 27;115(21):4206-16.
  • Adamia S, Pilarski PM, Belch AR, Pilarski LM.Genetic abnormalities in Waldenström's macroglobulinemia.Clin Lymphoma Myeloma. 2009 Mar;9(1):30-2.
  • Leleu X,Soumerai J,Roccaro A,Hatjiharissi E,Hunter ZR,Manning R,Ciccarelli BT,Sacco A,Ioakimidis L,Adamia S,Moreau AS,Patterson CJ,Ghobrial IM,Treon SP.Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs.J Clin Oncol. 2009 Jan 10;27(2):250-5.
  • Adamia S,Reichert AA,Kuppusamy H,Kriangkum J,Ghosh A,Hodges JJ,Pilarski PM,Treon SP,Mant MJ,Reiman T,Belch AR,Pilarski LM.Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.Blood. 2008 Dec 15;112(13):5111-21.
  • Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD.Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.Mol Cancer Ther. 2008 May;7(5):1121-9.
  • Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP.Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.Exp Hematol. 2007 Sep;35(9):1366-75.
  • VanDijken J, Kaigala GV, Lauzon J, Atrazhev A, Adamia S, Taylor BJ, Reiman T, Belch AR, Backhouse CJ, Pilarski LM.Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.J Mol Diagn. 2007 Jul;9(3):358-67.
  • Pilarski PM, Adamia S, Backhouse CJ.An adaptable microvalving system for on-chip polymerase chain reactions.J Immunol Methods. 2005 Oct 20;305(1):48-58.
  • Pilarski LM, Lauzon J, Strachan E, Adamia S, Atrazhev A, Belch AR, Backhouse CJ.Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma.J Immunol Methods. 2005 Oct 20;305(1):94-105.
  • Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM.Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.Blood. 2005 Jun 15;105(12):4836-44.
  • Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM.Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.Clin Lymphoma. 2005 Mar;5(4):253-6.
  • Adamia S, Maxwell CA, Pilarski LM.Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer.Curr Drug Targets Cardiovasc Haematol Disord. 2005 Feb;5(1):3-14. Review.
  • Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Reiman T.RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.Blood. 2004 Aug 15;104(4):1151-8.
  • Cen EG, Dalton C, Li Y, Adamia S, Pilarski LM, Kaler KV.A combined dielectrophoresis, traveling wave dielectrophoresis and electrorotation microchip for the manipulation and characterization of human malignant cells.Journal Of Microbiological Methods. 2004 Sep;58(3):387-401.
  • Adamia S, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM.Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia.Semin Oncol. 2003 Apr;30(2):165-8.